Literature DB >> 16867903

Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.

Hideaki Nakajima1, Fumi Shibata, Hidetoshi Kumagai, Kazuya Shimoda, Toshio Kitamura.   

Abstract

Internal tandem duplication of FLT3 tyrosine kinase (FLT3-ITD) is the most prevalent mutation found in acute myelogenous leukemia (AML), having been identified in 20% to 30% of all AML patients. We have previously shown that FLT3-ITD signals mainly through the signal transducer and activator of transcription 5 (STAT5) pathway and have suggested the possible involvement of Tyk2 in STAT5 activation by FLT3-ITD. The present study addressed the role of Tyk2 in FLT3-ITD signaling in a murine bone marrow transplantation (BMT) model. Transplantation of wild-type bone marrow cells transduced with the FLT3-ITD gene induced lethal myeloproliferative disease (MPD) in the recipient mice at a median latency of 89 days. Interestingly, some mice presented the proliferation of B- or T-lymphoid blasts in various organs, a presentation that resembled acute lymphoblastic leukemia (ALL). Mice that received Tyk2-deficient bone marrow cells transduced with FLT3-ITD developed lethal MPD with a disease latency (median, 100 days) and pathologic picture similar to those of mice that received wild-type bone marrow cells. These results indicate that (1) Tyk2 is not essential for MPD induction by FLT3-ITD and (2) FLT3-ITD by itself can induce ALL in a murine BMT model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16867903     DOI: 10.1532/IJH97.06016

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.

Authors:  F M Abu-Duhier; A C Goodeve; G A Wilson; R S Care; I R Peake; J T Reilly
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

2.  Immune suppressor factor confers stromal cell line with enhanced supporting activity for hematopoietic stem cells.

Authors:  Hideaki Nakajima; Fumi Shibata; Yumi Fukuchi; Yuko Goto-Koshino; Miyuki Ito; Atsushi Urano; Tatsutoshi Nakahata; Hiroyuki Aburatani; Toshio Kitamura
Journal:  Biochem Biophys Res Commun       Date:  2005-12-06       Impact factor: 3.575

3.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.

Authors:  Ryoichi Ono; Hideaki Nakajima; Katsutoshi Ozaki; Hidetoshi Kumagai; Toshiyuki Kawashima; Tomohiko Taki; Toshio Kitamura; Yasuhide Hayashi; Tetsuya Nosaka
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

5.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Authors:  Y Yamamoto; H Kiyoi; Y Nakano; R Suzuki; Y Kodera; S Miyawaki; N Asou; K Kuriyama; F Yagasaki; C Shimazaki; H Akiyama; K Saito; M Nishimura; T Motoji; K Shinagawa; A Takeshita; H Saito; R Ueda; R Ohno; T Naoe
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

6.  Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function.

Authors:  K Shimoda; K Kato; K Aoki; T Matsuda; A Miyamoto; M Shibamori; M Yamashita; A Numata; K Takase; S Kobayashi; S Shibata; Y Asano; H Gondo; K Sekiguchi; K Nakayama; T Nakayama; T Okamura; S Okamura; Y Niho; K Nakayama
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

7.  Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan.

Authors:  T Iwai; S Yokota; M Nakao; T Okamoto; M Taniwaki; N Onodera; A Watanabe; A Kikuta; A Tanaka; K Asami; I Sekine; H Mugishima; Y Nishimura; S Koizumi; Y Horikoshi; J Mimaya; S Ohta; K Nishikawa; A Iwai; T Shimokawa; M Nakayama; K Kawakami; T Gushiken; N Hyakuna; T Fujimoto
Journal:  Leukemia       Date:  1999-01       Impact factor: 11.528

8.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

Authors:  M Nakao; S Yokota; T Iwai; H Kaneko; S Horiike; K Kashima; Y Sonoda; T Fujimoto; S Misawa
Journal:  Leukemia       Date:  1996-12       Impact factor: 11.528

Review 9.  The roles of FLT3 in hematopoiesis and leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

10.  Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.

Authors:  S Zhang; S Fukuda; Y Lee; G Hangoc; S Cooper; R Spolski; W J Leonard; H E Broxmeyer
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

View more
  2 in total

Review 1.  TYK2: An Upstream Kinase of STATs in Cancer.

Authors:  Katharina Wöss; Natalija Simonović; Birgit Strobl; Sabine Macho-Maschler; Mathias Müller
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

2.  Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.

Authors:  Min Wang; Na He; Tian Tian; Lu Liu; Shuang Yu; Daoxin Ma
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.